{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:22:31Z","timestamp":1771474951837,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,8]]},"DOI":"10.7759\/cureus.87557","type":"journal-article","created":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:54:41Z","timestamp":1752069281000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of Renin-Angiotensin-Aldosterone System Modulation on Cognitive and Neuropsychiatric Outcomes: A Systematic Review of Clinical and Mechanistic Evidence"],"prefix":"10.7759","author":[{"given":"Muhammad Kamal","family":"Subhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Astrit","family":"Sabani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osman","family":"Omer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatima","family":"Kheirelsid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abeer K","family":"Srour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.17226\/25064","article-title":"Cognitive aging, dementia, and the future of an aging population","author":"Langa KM","year":"2018","unstructured":"Langa KM. Cognitive aging, dementia, and the future of an aging population. Future Directions for the Demography of Aging: Proceedings of a Workshop. National Academies Press, Washington, DC; 2018.  10.17226\/25064"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.36255\/exonpublications.alzheimersdisease.2020.ch1","article-title":"Alzheimer\u2019s disease: etiology, neuropathology and pathogenesis","author":"Sheppard O","year":"2020","unstructured":"Sheppard O, Coleman M. Alzheimer\u2019s disease: etiology, neuropathology and pathogenesis. Alzheimer\u2019s Disease: Drug Discovery. Huang X (ed): Exon Publications, Brisbane; 2020. 10.36255\/exonpublications.alzheimersdisease.2020.ch1"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13010016","article-title":"A new perspective on the renin-angiotensin system","volume":"13","author":"Martyniak A","year":"2022","unstructured":"Martyniak A, Tomasik PJ. A new perspective on the renin-angiotensin system. Diagnostics (Basel). 2022, 13:16. 10.3390\/diagnostics13010016","journal-title":"Diagnostics (Basel)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.149400","article-title":"The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update","volume":"1850","author":"Yasmin S","year":"2025","unstructured":"Yasmin S, Ashique S, Taj T, et al.. The role of ACE inhibitors and ARBs in preserving cognitive function via hypertension Management: A critical Update. Brain Res. 2025, 1850:149400. 10.1016\/j.brainres.2024.149400","journal-title":"Brain Res"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: An update","volume":"27","author":"Abiodun OA","year":"2020","unstructured":"Abiodun OA, Ola MS. Role of brain renin angiotensin system in neurodegeneration: An update. Saudi J Biol Sci. 2020, 27:905-12. 10.1016\/j.sjbs.2020.01.026","journal-title":"Saudi J Biol Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2016.10.002","article-title":"Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?","volume":"59","author":"Bavishi C","year":"2016","unstructured":"Bavishi C, Bangalore S, Messerli FH. Renin angiotensin aldosterone system inhibitors in hypertension: is there evidence for benefit independent of blood pressure reduction?. Prog Cardiovasc Dis. 2016, 59:253-61. 10.1016\/j.pcad.2016.10.002","journal-title":"Prog Cardiovasc Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00263-5","article-title":"Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial","volume":"20","author":"Kehoe PG","year":"2021","unstructured":"Kehoe PG, Turner N, Howden B, et al.. Safety and efficacy of losartan for the reduction of brain atrophy in clinically diagnosed Alzheimer's disease (the RADAR trial): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2021, 20:895-906. 10.1016\/S1474-4422(21)00263-5","journal-title":"Lancet Neurol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(10)70250-7","article-title":"Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies","volume":"10","author":"Anderson C","year":"2011","unstructured":"Anderson C, Teo K, Gao P, et al.. Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. Lancet Neurol. 2011, 10:43-53. 10.1016\/S1474-4422(10)70250-7","journal-title":"Lancet Neurol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14838","article-title":"Effect of renin-angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial","volume":"24","author":"Wharton W","year":"2022","unstructured":"Wharton W, Anderson A, Hayden KM, et al.. Effect of renin-angiotensin system antihypertensive medication use on cognitive function in diabetes mellitus with obesity or overweight: An ancillary study to the Action for Health in Diabetes (Look AHEAD) trial. Diabetes Obes Metab. 2022, 24:2443-53. 10.1111\/dom.14838","journal-title":"Diabetes Obes Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/1524839919893361","article-title":"A review of the PubMed PICO tool: using evidence-based practice in health education","volume":"21","author":"Brown D","year":"2020","unstructured":"Brown D. A review of the PubMed PICO tool: using evidence-based practice in health education. Health Promot Pract. 2020, 21:496-8. 10.1177\/1524839919893361","journal-title":"Health Promot Pract"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1262-x","article-title":"RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial","volume":"15","author":"Ahmed HA","year":"2018","unstructured":"Ahmed HA, Ishrat T, Pillai B, et al.. RAS modulation prevents progressive cognitive impairment after experimental stroke: a randomized, blinded preclinical trial. J Neuroinflammation. 2018, 15:229. 10.1186\/s12974-018-1262-x","journal-title":"J Neuroinflammation"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11357-014-9646-z","article-title":"ACE polymorphism and use of ACE inhibitors: effects on memory performance","volume":"36","author":"Schuch JB","year":"2014","unstructured":"Schuch JB, Constantin PC, da Silva VK, et al.. ACE polymorphism and use of ACE inhibitors: effects on memory performance. Age (Dordr). 2014, 36:9646. 10.1007\/s11357-014-9646-z","journal-title":"Age (Dordr)"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1470320314529356","article-title":"Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes","volume":"16","author":"F\u00e6rch LH","year":"2015","unstructured":"F\u00e6rch LH, Thorsteinsson B, Tarnow L, et al.. Effects of angiotensin II receptor blockade on cerebral, cardiovascular, counter-regulatory, and symptomatic responses during hypoglycaemia in patients with type 1 diabetes. J Renin Angiotensin Aldosterone Syst. 2015, 16:1036-45. 10.1177\/1470320314529356","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e328301a280","article-title":"Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study","volume":"26","author":"Hanon O","year":"2008","unstructured":"Hanon O, Berrou JP, Negre-Pages L, et al.. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008, 26:1642-50. 10.1097\/HJH.0b013e328301a280","journal-title":"J Hypertens"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-14-43","article-title":"SYRCLE's risk of bias tool for animal studies","volume":"14","author":"Hooijmans CR","year":"2014","unstructured":"Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. BMC Med Res Methodol. 2014, 14:43. 10.1186\/1471-2288-14-43","journal-title":"BMC Med Res Methodol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010783.pub3","article-title":"Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)","volume":"7","author":"Arevalo-Rodriguez I","year":"2021","unstructured":"Arevalo-Rodriguez I, Smailagic N, Roqu\u00e9-Figuls M, et al.. Mini-Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI). Cochrane Database Syst Rev. 2021, 7:CD010783. 10.1002\/14651858.CD010783.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-023-01435-8","article-title":"The renin angiotensin system as a therapeutic target in traumatic brain injury","volume":"20","author":"Villapol S","year":"2023","unstructured":"Villapol S, Janatpour ZC, Affram KO, Symes AJ. The renin angiotensin system as a therapeutic target in traumatic brain injury. Neurotherapeutics. 2023, 20:1565-91. 10.1007\/s13311-023-01435-8","journal-title":"Neurotherapeutics"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.07.002","article-title":"Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition","volume":"1","author":"Bottinor WJ","year":"2019","unstructured":"Bottinor WJ, Shuey MM, Manouchehri A, et al.. Renin-angiotensin-aldosterone system modulates blood pressure response during vascular endothelial growth factor receptor inhibition. JACC CardioOncol. 2019, 1:14-23. 10.1016\/j.jaccao.2019.07.002","journal-title":"JACC CardioOncol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-9-48","article-title":"The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition","volume":"9","author":"Hajjar I","year":"2009","unstructured":"Hajjar I, Hart M, Milberg W, Novak V, Lipsitz L. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr. 2009, 9:48. 10.1186\/1471-2318-9-48","journal-title":"BMC Geriatr"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000678","article-title":"2019ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett DK","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al.. 2019ACC\/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019, 140:e596-646. 10.1161\/CIR.0000000000000678","journal-title":"Circulation"},{"key":"ref24","unstructured":"National Institute for Health and Care Excellence (NICE). Hypertension in adults. diagnosis and management. (2019). Accessed: July 7, 2025: https:\/\/www.nice.org.uk\/guidance\/ng136\/chapter\/recommendations."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.13251","article-title":"Dysregulation of the renin-angiotensin system in vascular dementia","volume":"34","author":"Tayler HM","year":"2024","unstructured":"Tayler HM, Skrobot OA, Baron DH, Kehoe PG, Miners JS. Dysregulation of the renin-angiotensin system in vascular dementia. Brain Pathol. 2024, 34:e13251. 10.1111\/bpa.13251","journal-title":"Brain Pathol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376096-impact-of-renin-angiotensin-aldosterone-system-modulation-on-cognitive-and-neuropsychiatric-outcomes-a-systematic-review-of-clinical-and-mechanistic-evidence","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,9]],"date-time":"2025-07-09T13:54:42Z","timestamp":1752069282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376096-impact-of-renin-angiotensin-aldosterone-system-modulation-on-cognitive-and-neuropsychiatric-outcomes-a-systematic-review-of-clinical-and-mechanistic-evidence"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,8]]},"references-count":25,"URL":"https:\/\/doi.org\/10.7759\/cureus.87557","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,8]]}}}